newsfilter
← Latest News
GlobeNewswire·

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in